A brief review of the pharmacology of amitriptyline and clinical outcomes in treating fibromyalgia

LAWSON, Kim (2017). A brief review of the pharmacology of amitriptyline and clinical outcomes in treating fibromyalgia. Biomedicines, 5 (2), p. 24.

biomedicines-05-00024.pdf - Published Version
Creative Commons Attribution.

Download (385kB) | Preview
Official URL: http://www.mdpi.com/2227-9059/5/2/24
Link to published version:: https://doi.org/10.3390/biomedicines5020024


Fibromyalgia is a complex chronic condition characterized by pain, physical fatigue, sleep disorder and cognitive impairment. Evidence-based guidelines recommend antidepressants as treatments of fibromyalgia where tricyclics are often considered to have the greatest efficacy, with amitriptyline often being a first-line treatment. Amitriptyline evokes a preferential reduction in pain and fatigue of fibromyalgia, and in the Fibromyalgia Impact Questionnaire (FIQ) score, which is a quality of life assessment. The multimodal profile of the mechanisms of action of amitriptyline include monoamine reuptake inhibition, receptor modulation and ion channel modulation. Several of the actions of amitriptyline on multiple nociceptive and sensory processes at central and peripheral locations have the potential to act cumulatively to suppress the characteristic symptoms of fibromyalgia. Greater understanding of the role of these mechanisms of action of amitriptyline could provide further clues to the pathophysiology of fibromyalgia and to a preferable pharmacological profile for future drug development

Item Type: Article
Departments - Does NOT include content added after October 2018: Health and Well-being > Department of Bioscience
Identification Number: https://doi.org/10.3390/biomedicines5020024
Page Range: p. 24
Depositing User: Kim Lawson
Date Deposited: 26 May 2017 13:16
Last Modified: 18 Mar 2021 04:07
URI: https://shura.shu.ac.uk/id/eprint/15783

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics